Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


Product Development Plan


All APR products and projects are based on a solid set of scientific data and/or proven technologies but in addition, they are also complemented, supported and maximized by an integrated strategic marketing model.


We define and coordinate the value chain from R&D and technology investments to the final consumer targets in order to deliver competitive products for our healthcare partners as well as effective added value products for patients and consumers.


We focus on strategic product planning: we internally analyze markets, trends and brands in order to identify new product /project opportunities, we identify the best development path for any product/project and we execute and control all the phases in order to deliver to our partners validated products; we finally support our partners and customers during all the launch phases and the commercial lifecycle with an integrated marketing plan.





Search results